Hemodialysis catheter locking solutions and the prevention of catheter dysfunction: A meta-analysis

Kevin Chapla, Bharvi P. Oza-Gajera, Alexander S. Yevzlin, Jung-Im Shin, Brad C. Astor, Micah R. Chan

Research output: Contribution to journalArticle

Abstract

Purpose: Tunneled dialysis catheters (TDCs) continue to be utilized at an alarming rate despite having a higher rate of complications when compared to fistulas and grafts. One of the primary complications of TDCs involves catheter dysfunction resulting in reduced blood flow and poor dialysis adequacy, often requiring catheter removal in addition to thrombolytic therapy. Our objective was to compare the use of locking solutions containing heparin versus all other locking solutions for primary prevention of TDC dysfunction. Methods: We searched Medline for English language literature from 1980 through December 2013, along with national conference proceedings and reference lists of all included publications to identify relevant studies. Inclusion criteria were a measure of incidence of catheter dysfunction, catheter exchange or use of thrombolytic therapy. Studies were excluded if they were not in English or if they included pediatric patients. Random effects models were used to derive the pooled risk ratios. Results: Thirteen studies with a total of 1,883 subjects met the inclusion criteria. There was no significant difference in catheter patency in those receiving heparin versus those treated with other lock solutions (incidence rate ratio [IRR] 0.99; 95% confidence interval [CI] 0.66-1.48, p = 0.96). Catheter patency did not differ between treatments in experimental studies (n = 10; IRR = 0.89; 95% CI: 0.56-1.39, p = 0.60) or observational design (n = 3; IRR = 1.64; 95% CI 0.40-6.85, p = 0.50). Significant heterogeneity was detected across studies (I2 = 84.4%, p<0.001). Conclusions: Our results suggest that there is no substantial difference between heparin lock solutions versus all other types of catheter lock solutions for catheter dysfunction. Whether there are significant benefits of citrate or other novel lock solutions requires further robust studies. These findings have significant implications for future design of clinical trials in TDCs and the delivery of dialysis-related services.

Original languageEnglish (US)
Pages (from-to)107-112
Number of pages6
JournalJournal of Vascular Access
Volume16
Issue number2
DOIs
StatePublished - Mar 1 2015
Externally publishedYes

Fingerprint

Renal Dialysis
Meta-Analysis
Catheters
Dialysis
Heparin
Thrombolytic Therapy
Incidence
Confidence Intervals
Primary Prevention
Citric Acid
Fistula
Publications
Language
Odds Ratio
Clinical Trials
Pediatrics
Transplants

Keywords

  • Catheter dysfunction
  • Dialysis access
  • Dialysis catheter
  • Vascular access

ASJC Scopus subject areas

  • Surgery
  • Nephrology

Cite this

Hemodialysis catheter locking solutions and the prevention of catheter dysfunction : A meta-analysis. / Chapla, Kevin; Oza-Gajera, Bharvi P.; Yevzlin, Alexander S.; Shin, Jung-Im; Astor, Brad C.; Chan, Micah R.

In: Journal of Vascular Access, Vol. 16, No. 2, 01.03.2015, p. 107-112.

Research output: Contribution to journalArticle

Chapla, Kevin ; Oza-Gajera, Bharvi P. ; Yevzlin, Alexander S. ; Shin, Jung-Im ; Astor, Brad C. ; Chan, Micah R. / Hemodialysis catheter locking solutions and the prevention of catheter dysfunction : A meta-analysis. In: Journal of Vascular Access. 2015 ; Vol. 16, No. 2. pp. 107-112.
@article{037d3a64e7ac4966a8f82749d253b7b1,
title = "Hemodialysis catheter locking solutions and the prevention of catheter dysfunction: A meta-analysis",
abstract = "Purpose: Tunneled dialysis catheters (TDCs) continue to be utilized at an alarming rate despite having a higher rate of complications when compared to fistulas and grafts. One of the primary complications of TDCs involves catheter dysfunction resulting in reduced blood flow and poor dialysis adequacy, often requiring catheter removal in addition to thrombolytic therapy. Our objective was to compare the use of locking solutions containing heparin versus all other locking solutions for primary prevention of TDC dysfunction. Methods: We searched Medline for English language literature from 1980 through December 2013, along with national conference proceedings and reference lists of all included publications to identify relevant studies. Inclusion criteria were a measure of incidence of catheter dysfunction, catheter exchange or use of thrombolytic therapy. Studies were excluded if they were not in English or if they included pediatric patients. Random effects models were used to derive the pooled risk ratios. Results: Thirteen studies with a total of 1,883 subjects met the inclusion criteria. There was no significant difference in catheter patency in those receiving heparin versus those treated with other lock solutions (incidence rate ratio [IRR] 0.99; 95{\%} confidence interval [CI] 0.66-1.48, p = 0.96). Catheter patency did not differ between treatments in experimental studies (n = 10; IRR = 0.89; 95{\%} CI: 0.56-1.39, p = 0.60) or observational design (n = 3; IRR = 1.64; 95{\%} CI 0.40-6.85, p = 0.50). Significant heterogeneity was detected across studies (I2 = 84.4{\%}, p<0.001). Conclusions: Our results suggest that there is no substantial difference between heparin lock solutions versus all other types of catheter lock solutions for catheter dysfunction. Whether there are significant benefits of citrate or other novel lock solutions requires further robust studies. These findings have significant implications for future design of clinical trials in TDCs and the delivery of dialysis-related services.",
keywords = "Catheter dysfunction, Dialysis access, Dialysis catheter, Vascular access",
author = "Kevin Chapla and Oza-Gajera, {Bharvi P.} and Yevzlin, {Alexander S.} and Jung-Im Shin and Astor, {Brad C.} and Chan, {Micah R.}",
year = "2015",
month = "3",
day = "1",
doi = "10.5301/jva.5000312",
language = "English (US)",
volume = "16",
pages = "107--112",
journal = "Journal of Vascular Access",
issn = "1129-7298",
publisher = "Wichtig Publishing",
number = "2",

}

TY - JOUR

T1 - Hemodialysis catheter locking solutions and the prevention of catheter dysfunction

T2 - A meta-analysis

AU - Chapla, Kevin

AU - Oza-Gajera, Bharvi P.

AU - Yevzlin, Alexander S.

AU - Shin, Jung-Im

AU - Astor, Brad C.

AU - Chan, Micah R.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Purpose: Tunneled dialysis catheters (TDCs) continue to be utilized at an alarming rate despite having a higher rate of complications when compared to fistulas and grafts. One of the primary complications of TDCs involves catheter dysfunction resulting in reduced blood flow and poor dialysis adequacy, often requiring catheter removal in addition to thrombolytic therapy. Our objective was to compare the use of locking solutions containing heparin versus all other locking solutions for primary prevention of TDC dysfunction. Methods: We searched Medline for English language literature from 1980 through December 2013, along with national conference proceedings and reference lists of all included publications to identify relevant studies. Inclusion criteria were a measure of incidence of catheter dysfunction, catheter exchange or use of thrombolytic therapy. Studies were excluded if they were not in English or if they included pediatric patients. Random effects models were used to derive the pooled risk ratios. Results: Thirteen studies with a total of 1,883 subjects met the inclusion criteria. There was no significant difference in catheter patency in those receiving heparin versus those treated with other lock solutions (incidence rate ratio [IRR] 0.99; 95% confidence interval [CI] 0.66-1.48, p = 0.96). Catheter patency did not differ between treatments in experimental studies (n = 10; IRR = 0.89; 95% CI: 0.56-1.39, p = 0.60) or observational design (n = 3; IRR = 1.64; 95% CI 0.40-6.85, p = 0.50). Significant heterogeneity was detected across studies (I2 = 84.4%, p<0.001). Conclusions: Our results suggest that there is no substantial difference between heparin lock solutions versus all other types of catheter lock solutions for catheter dysfunction. Whether there are significant benefits of citrate or other novel lock solutions requires further robust studies. These findings have significant implications for future design of clinical trials in TDCs and the delivery of dialysis-related services.

AB - Purpose: Tunneled dialysis catheters (TDCs) continue to be utilized at an alarming rate despite having a higher rate of complications when compared to fistulas and grafts. One of the primary complications of TDCs involves catheter dysfunction resulting in reduced blood flow and poor dialysis adequacy, often requiring catheter removal in addition to thrombolytic therapy. Our objective was to compare the use of locking solutions containing heparin versus all other locking solutions for primary prevention of TDC dysfunction. Methods: We searched Medline for English language literature from 1980 through December 2013, along with national conference proceedings and reference lists of all included publications to identify relevant studies. Inclusion criteria were a measure of incidence of catheter dysfunction, catheter exchange or use of thrombolytic therapy. Studies were excluded if they were not in English or if they included pediatric patients. Random effects models were used to derive the pooled risk ratios. Results: Thirteen studies with a total of 1,883 subjects met the inclusion criteria. There was no significant difference in catheter patency in those receiving heparin versus those treated with other lock solutions (incidence rate ratio [IRR] 0.99; 95% confidence interval [CI] 0.66-1.48, p = 0.96). Catheter patency did not differ between treatments in experimental studies (n = 10; IRR = 0.89; 95% CI: 0.56-1.39, p = 0.60) or observational design (n = 3; IRR = 1.64; 95% CI 0.40-6.85, p = 0.50). Significant heterogeneity was detected across studies (I2 = 84.4%, p<0.001). Conclusions: Our results suggest that there is no substantial difference between heparin lock solutions versus all other types of catheter lock solutions for catheter dysfunction. Whether there are significant benefits of citrate or other novel lock solutions requires further robust studies. These findings have significant implications for future design of clinical trials in TDCs and the delivery of dialysis-related services.

KW - Catheter dysfunction

KW - Dialysis access

KW - Dialysis catheter

KW - Vascular access

UR - http://www.scopus.com/inward/record.url?scp=84936748837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936748837&partnerID=8YFLogxK

U2 - 10.5301/jva.5000312

DO - 10.5301/jva.5000312

M3 - Article

C2 - 25262758

AN - SCOPUS:84936748837

VL - 16

SP - 107

EP - 112

JO - Journal of Vascular Access

JF - Journal of Vascular Access

SN - 1129-7298

IS - 2

ER -